191 related articles for article (PubMed ID: 25251038)
1. Antitumor effects of tyropeptin-boronic acid derivatives: New proteasome inhibitors.
Momose I; Abe H; Watanabe T; Ohba S; Yamazaki K; Dan S; Yamori T; Masuda T; Nomoto A
Cancer Sci; 2014 Dec; 105(12):1609-15. PubMed ID: 25251038
[TBL] [Abstract][Full Text] [Related]
2. Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2.
Momose I; Watanabe T
J Antibiot (Tokyo); 2017 May; 70(5):542-550. PubMed ID: 28196975
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies.
Lei M; Feng H; Bai E; Zhou H; Wang J; Shi J; Wang X; Hu S; Liu Z; Zhu Y
Bioorg Med Chem; 2018 Aug; 26(14):3975-3981. PubMed ID: 29934218
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of boronic acid derivatives of tyropeptin: proteasome inhibitors.
Watanabe T; Momose I; Abe M; Abe H; Sawa R; Umezawa Y; Ikeda D; Takahashi Y; Akamatsu Y
Bioorg Med Chem Lett; 2009 Apr; 19(8):2343-5. PubMed ID: 19307118
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and activity of tyropeptin A derivatives as potent and selective inhibitors of mammalian 20S proteasome.
Momose I; Umezawa Y; Hirosawa S; Iijima M; Iinuma H; Ikeda D
Biosci Biotechnol Biochem; 2005 Sep; 69(9):1733-42. PubMed ID: 16195592
[TBL] [Abstract][Full Text] [Related]
8. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
Berenson JR; Ma HM; Vescio R
Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
[TBL] [Abstract][Full Text] [Related]
9. The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.
Kikuchi J; Yamada S; Koyama D; Wada T; Nobuyoshi M; Izumi T; Akutsu M; Kano Y; Furukawa Y
J Biol Chem; 2013 Aug; 288(35):25593-25602. PubMed ID: 23878197
[TBL] [Abstract][Full Text] [Related]
10. Design and discovery of novel dipeptide boronic acid ester proteasome inhibitors, an oral slowly-released prodrug for the treatment of multiple myeloma.
Wang X; Zhang W; Wen T; Miao H; Hu W; Liu H; Lei M; Zhu Y
Eur J Med Chem; 2023 Mar; 250():115187. PubMed ID: 36806958
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel dipeptidyl boronic acid proteasome inhibitor for the treatment of multiple myeloma and triple-negative breast cancer.
Lei M; Feng H; Bai E; Zhou H; Wang J; Qin Y; Zhang H; Wang X; Liu Z; Hai O; Liu J; Zhu Y
Org Biomol Chem; 2019 Jan; 17(3):683-691. PubMed ID: 30601533
[TBL] [Abstract][Full Text] [Related]
12. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.
Piva R; Ruggeri B; Williams M; Costa G; Tamagno I; Ferrero D; Giai V; Coscia M; Peola S; Massaia M; Pezzoni G; Allievi C; Pescalli N; Cassin M; di Giovine S; Nicoli P; de Feudis P; Strepponi I; Roato I; Ferracini R; Bussolati B; Camussi G; Jones-Bolin S; Hunter K; Zhao H; Neri A; Palumbo A; Berkers C; Ovaa H; Bernareggi A; Inghirami G
Blood; 2008 Mar; 111(5):2765-75. PubMed ID: 18057228
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of proteasome inhibition using a proteasome-sensitive fluorescent reporter.
Momose I; Tatsuda D; Ohba S; Masuda T; Ikeda D; Nomoto A
Cancer Sci; 2012 Sep; 103(9):1730-6. PubMed ID: 22676179
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
15. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
16. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo.
Tiedemann RE; Schmidt J; Keats JJ; Shi CX; Zhu YX; Palmer SE; Mao X; Schimmer AD; Stewart AK
Blood; 2009 Apr; 113(17):4027-37. PubMed ID: 19096011
[TBL] [Abstract][Full Text] [Related]
17. The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
Kraus J; Kraus M; Liu N; Besse L; Bader J; Geurink PP; de Bruin G; Kisselev AF; Overkleeft H; Driessen C
Cancer Chemother Pharmacol; 2015 Aug; 76(2):383-96. PubMed ID: 26099967
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
20. Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.
Lee KH; Jeong J; Yoo CG
J Biol Chem; 2013 Nov; 288(45):32777-32786. PubMed ID: 24085292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]